Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Bisphosphonates on OI-Related Hearing Loss
NCT04152551Phase 4Recruiting
- Sponsor
- Hospital for Special Surgery
- Start
- Nov 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of risedronate in osteogenesis imperfecta (OI) and hearing loss (4 arms), sponsored by Hospital for Special Surgery. Primary endpoint: Pure Tone Averages at 60 months. Started Nov 2019; status: recruiting.
02
Drugs
risedronate
03
Conditions
osteogenesis imperfecta (OI)hearing loss
Beyond the preview
Go deeper on NCT04152551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152551.